A third CD19-targeted CAR-T, Bristol-Myers Squibb's Breyanzi (lisocabtagene maraleucel), is on the market for other blood cancers, but not ALL. Aucatzyl will now have to carve out market share ...

Still, the economic and market outlook this year seems cloudier than usual, due largely to stiff tariff increases and policy ...

Prospective UK undergraduate students can apply for a range of funding provided by donations from friends and alumni of the University of Bristol. The application for additional funding is a process ...

Almost exactly three years after agreeing on a $2.6 billion deal to acquire Aimmune Therapeutics and its peanut allergy therapy Palforzia, food group Nestle has sold off the business. This morning ...

57% of the University's research achieved the top 'world-leading' 4* rating, compared to a sector average of 41%. 37% of Bristol's research was judged to be 'internationally excellent' and received ...